Anti-muscle specific tyrosine kinase antibody-associated myasthenia gravis (MuSK-MG) is a rare subtype of MG characterized by more frequent relapses and a clinical course that is refractory to standard treatments. Rituximab, a monoclonal antibody targeting CD20+ B cells, has been used effectively in the adult population to achieve stable remission. We describe a pediatric patient with MuSK-MG who demonstrated an excellent response to rituximab after failing standard therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/2576117X.2019.1578164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis.
Eur J Neurol
January 2025
Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau; and Institut de Recerca Sant Pau, IR-SantPau, Barcelona, Spain.
Article Synopsis
- The study focuses on long-term outcomes and healthcare resource utilization in patients with generalized myasthenia gravis (gMG).
- About 220 patients were analyzed over eight years, showing significant improvement in daily living scores and a reduction in healthcare costs, although some patients continued to experience symptoms and drug-related adverse events.
- The findings suggest that while most patients experience positive outcomes, a minority still suffer from persistent symptoms and side effects, highlighting the ongoing burden of gMG on both patients and healthcare systems.
Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review.
Neuroepidemiology
October 2024
Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Article Synopsis
- A systematic review was conducted to estimate the global prevalence, incidence, and mortality rates of myasthenia gravis (MG) and related syndromes, due to a gap in recent investigations.
- The review analyzed 94 studies published from 1952 to 2022, finding a mean prevalence of 173.3 cases per million, a mean incidence of 15.7 cases per million person-years, and a mean mortality rate of 1.4 cases per million person-years, with acetylcholine receptor (AChR)-MG being the most common subtype.
- The review highlighted that the significant increase in reported MG cases may stem from enhanced research methods and diagnostic tools, though variations in MG frequencies exist due to
Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study.
Ther Adv Neurol Disord
September 2024
Department of Neurology, University Health Network, Toronto, ON, Canada.
Article Synopsis
- The study investigates the effectiveness and safety of rozanolixizumab in treating patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive generalized myasthenia gravis (gMG), which is a severe form of the condition.
- Conducted as a randomized, double-blind, placebo-controlled phase III trial, it involved participants aged 18 and older who were randomly assigned to receive either rozanolixizumab (at two different dosages) or a placebo over 6 weeks.
- Results showed significant improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scores for both doses of rozanolixizumab compared to placebo, with manageable side effects reported;
Wilson's Disease-Crossroads of Genetics, Inflammation and Immunity/Autoimmunity: Clinical and Molecular Issues.
Int J Mol Sci
August 2024
Second Department of Neurology, Institute of Psychiatry and Neurology, Sobieskiego Street 9, 02-957 Warsaw, Poland.
Article Synopsis
- Wilson's disease (WD) is a genetic disorder that disrupts copper metabolism, leading to copper overload, potential cell death, and varied clinical symptoms that can appear at any age.
- Immunological abnormalities, including increased IgG and IgM levels and decreased T lymphocyte activity, have been observed in WD patients, highlighting a complex interaction between copper and inflammation.
- Research has identified various autoimmune responses in WD patients, with the presence of autoantibodies occurring independently of treatment type, yet their clinical implications remain unclear.
Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series.
Front Immunol
August 2024
Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Article Synopsis
- Efgartigimod has shown effectiveness and safety in treating myasthenic crisis (MC) patients, leading to successful ventilation weaning.
- The study involved 10 patients, assessing their improvement through the MG-ADL scale and measuring immune markers before and after treatment.
- Results indicated significant reductions in MG-ADL scores and corticosteroid dosages, along with changes in specific T cell populations following efgartigimod therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!